Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

180 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
MiRNA-449 family is epigenetically repressed and sensitizes to doxorubicin through ACSL4 downregulation in triple-negative breast cancer.
Torres-Ruiz S, Garrido-Cano I, Lameirinhas A, Burgués O, Hernando C, Martínez MT, Rojo F, Bermejo B, Tapia M, Carbonell-Asins JA, Peña CJ, Lluch A, Cejalvo JM, Tormo E, Eroles P. Torres-Ruiz S, et al. Among authors: bermejo b. Cell Death Discov. 2024 Aug 22;10(1):372. doi: 10.1038/s41420-024-02128-7. Cell Death Discov. 2024. PMID: 39174500 Free PMC article.
High VEGFR3 Expression Reduces Doxorubicin Efficacy in Triple-Negative Breast Cancer.
Torres-Ruiz S, Tormo E, Garrido-Cano I, Lameirinhas A, Rojo F, Madoz-Gúrpide J, Burgués O, Hernando C, Bermejo B, Martínez MT, Lluch A, Cejalvo JM, Eroles P. Torres-Ruiz S, et al. Among authors: bermejo b. Int J Mol Sci. 2023 Feb 10;24(4):3601. doi: 10.3390/ijms24043601. Int J Mol Sci. 2023. PMID: 36835014 Free PMC article.
miR-146a-5p Promotes Angiogenesis and Confers Trastuzumab Resistance in HER2+ Breast Cancer.
Cabello P, Torres-Ruiz S, Adam-Artigues A, Forés-Martos J, Martínez MT, Hernando C, Zazo S, Madoz-Gúrpide J, Rovira A, Burgués O, Rojo F, Albanell J, Lluch A, Bermejo B, Cejalvo JM, Eroles P. Cabello P, et al. Among authors: bermejo b. Cancers (Basel). 2023 Apr 4;15(7):2138. doi: 10.3390/cancers15072138. Cancers (Basel). 2023. PMID: 37046799 Free PMC article.
Delivery of miR-200c-3p Using Tumor-Targeted Mesoporous Silica Nanoparticles for Breast Cancer Therapy.
Garrido-Cano I, Adam-Artigues A, Lameirinhas A, Blandez JF, Candela-Noguera V, Lluch A, Bermejo B, Sancenón F, Cejalvo JM, Martínez-Máñez R, Eroles P. Garrido-Cano I, et al. Among authors: bermejo b. ACS Appl Mater Interfaces. 2023 Aug 16;15(32):38323-38334. doi: 10.1021/acsami.3c07541. Epub 2023 Aug 7. ACS Appl Mater Interfaces. 2023. PMID: 37549382 Free PMC article.
Clinical Impact of New Treatment Strategies for HER2-Positive Metastatic Breast Cancer Patients with Resistance to Classical Anti-HER Therapies.
Tapia M, Hernando C, Martínez MT, Burgués O, Tebar-Sánchez C, Lameirinhas A, Ágreda-Roca A, Torres-Ruiz S, Garrido-Cano I, Lluch A, Bermejo B, Eroles P. Tapia M, et al. Among authors: bermejo b. Cancers (Basel). 2023 Sep 12;15(18):4522. doi: 10.3390/cancers15184522. Cancers (Basel). 2023. PMID: 37760491 Free PMC article. Review.
NK cell-triggered CCL5/IFNγ-CXCL9/10 axis underlies the clinical efficacy of neoadjuvant anti-HER2 antibodies in breast cancer.
Santana-Hernández S, Suarez-Olmos J, Servitja S, Berenguer-Molins P, Costa-Garcia M, Comerma L, Rea A, Perera-Bel J, Menendez S, Arpí O, Bermejo B, Martínez MT, Cejalvo JM, Comino-Méndez I, Pascual J, Alba E, López-Botet M, Rojo F, Rovira A, Albanell J, Muntasell A. Santana-Hernández S, et al. Among authors: bermejo b. J Exp Clin Cancer Res. 2024 Jan 3;43(1):10. doi: 10.1186/s13046-023-02918-4. J Exp Clin Cancer Res. 2024. PMID: 38167224 Free PMC article.
Biomarkers in breast cancer 2024: an updated consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology.
Colomer R, González-Farré B, Ballesteros AI, Peg V, Bermejo B, Pérez-Mies B, de la Cruz S, Rojo F, Pernas S, Palacios J. Colomer R, et al. Among authors: bermejo b. Clin Transl Oncol. 2024 Dec;26(12):2935-2951. doi: 10.1007/s12094-024-03541-1. Epub 2024 Jun 13. Clin Transl Oncol. 2024. PMID: 38869741 Free PMC article.
Spatial predictors of immunotherapy response in triple-negative breast cancer.
Wang XQ, Danenberg E, Huang CS, Egle D, Callari M, Bermejo B, Dugo M, Zamagni C, Thill M, Anton A, Zambelli S, Russo S, Ciruelos EM, Greil R, Győrffy B, Semiglazov V, Colleoni M, Kelly CM, Mariani G, Del Mastro L, Biasi O, Seitz RS, Valagussa P, Viale G, Gianni L, Bianchini G, Ali HR. Wang XQ, et al. Among authors: bermejo b. Nature. 2023 Sep;621(7980):868-876. doi: 10.1038/s41586-023-06498-3. Epub 2023 Sep 6. Nature. 2023. PMID: 37674077 Free PMC article.
Correlation between trophoblast cell-surface antigen-2 (Trop-2) expression and pathological complete response in patients with HER2-positive early breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab.
Gion M, García-Mosquera JJ, Pérez-García JM, Peg V, Ruiz-Borrego M, Stradella A, Bermejo B, Guerrero JA, López-Montero L, Mancino M, Rodríguez-Morató J, Antonarelli G, Sampayo-Cordero M, Llombart-Cussac A, Cortés J. Gion M, et al. Among authors: bermejo b. Breast Cancer Res Treat. 2024 Jun;205(3):589-598. doi: 10.1007/s10549-024-07292-z. Epub 2024 Mar 8. Breast Cancer Res Treat. 2024. PMID: 38456970
Long-term outcomes of high-risk HR-positive and HER2-negative early breast cancer patients from GEICAM adjuvant studies and El Álamo IV registry.
Martín M, Carrasco E, Rodríguez-Lescure Á, Andrés R, Servitja S, Antón A, Ruiz-Borrego M, Bermejo B, Guerrero Á, Ramos M, Santaballa A, Muñoz M, Cruz J, Lopez-Tarruella S, Chacón JI, Álvarez I, Martínez P, Miralles JJ, Polonio Ó, Jara C, Aguiar-Bujanda D. Martín M, et al. Among authors: bermejo b. Breast Cancer Res Treat. 2023 Sep;201(2):151-159. doi: 10.1007/s10549-023-07002-1. Epub 2023 Jun 20. Breast Cancer Res Treat. 2023. PMID: 37338729 Free PMC article. Review.
180 results